---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179834"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:13.293386+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acrivon Q2 net loss $21.0M, cash $147.6M; advances ACR-368 and ACR-2316 trials

## Summary
- Net loss of $21.0M for Q2 2025, up from $18.8M in Q2 2024; R&D spend $16.2M.
- Cash, equivalents and investments of $147.6M as of June 30, 2025; expected runway into Q2 2027.
- Initiated Phase 2b third arm for ACR-368 with ultra low-dose gemcitabine in biomarker-unselected endometrial cancer.
- ACR-2316 Phase 1 dose escalation shows initial clinical activity, including confirmed partial response in endometrial cancer.
- Anticipated H2 2025 milestones: update on registrational ACR-368 trial and initial Phase 1 data for ACR-2316.

## SEC filing metadata
- accession: 0001193125-25-179834
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312525179834/0001193125-25-179834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312525179834/acrv-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179834
- JSON: https://secwatch.observer/filing/0001193125-25-179834.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.